159 related articles for article (PubMed ID: 263317)
1. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients.
Camanni F; Picotti GB; Massara F; Molinatti GM; Mantegazza P; Müller EE
J Clin Endocrinol Metab; 1978 Sep; 47(3):647-52. PubMed ID: 263317
[TBL] [Abstract][Full Text] [Related]
2. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Fine SA; Frohman LA
J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
[TBL] [Abstract][Full Text] [Related]
4. [Studies on the abnormal response of pituitary somatotropin to dopaminergic drugs in patients with acromegaly].
Shi YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1990 Jun; 12(3):168-72. PubMed ID: 2150352
[TBL] [Abstract][Full Text] [Related]
5. Interaction between the thyrotrophin-releasing hormone-induced growth hormone rise and dopaminergic drugs: studies in pathologic conditions of the animal and man.
Müller EE; Salerno F; Cocchi D; Locatelli V; Panerai AE
Clin Endocrinol (Oxf); 1979 Dec; 11(6):645-56. PubMed ID: 119594
[TBL] [Abstract][Full Text] [Related]
6. Effects of CNS dopamine augmentation on stimulated prolactin secretion.
Woolf PD; Leebaw WJ; Lee LA
J Clin Endocrinol Metab; 1977 Oct; 45(4):857-60. PubMed ID: 410827
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic regulation of growth hormone (GH) secretion in normal man: correlation of L-dopa and dopamine levels with the GH response.
Bansal S; Lee LA; Woolf PD
J Clin Endocrinol Metab; 1981 Aug; 53(2):301-6. PubMed ID: 7251816
[No Abstract] [Full Text] [Related]
8. Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.
Molitch ME; Goodman RH; Post KD; Biller BJ; Moses AC; King LW; Feldman ZT; Reichlin S
J Clin Endocrinol Metab; 1982 Dec; 55(6):1118-23. PubMed ID: 7130339
[TBL] [Abstract][Full Text] [Related]
9. Abnormal growth hormone responsiveness to stimuli in women with active celiac sprue.
Peracchi M; Molteni N; Cantalamessa L; Bardella MT; Peracchi G; Orsatti A; Faggioli P; Bianchi PA
Am J Gastroenterol; 1992 May; 87(5):580-3. PubMed ID: 1595643
[TBL] [Abstract][Full Text] [Related]
10. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
Carlson HE
J Clin Endocrinol Metab; 1986 Jul; 63(1):249-51. PubMed ID: 3086358
[TBL] [Abstract][Full Text] [Related]
11. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
[TBL] [Abstract][Full Text] [Related]
12. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
Rao R; Scommegna A; Frohman LA
Am J Obstet Gynecol; 1982 Aug; 143(8):883-7. PubMed ID: 7102764
[TBL] [Abstract][Full Text] [Related]
13. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
[TBL] [Abstract][Full Text] [Related]
14. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Bell RD; Carruth A; Rosenberg RN; Boyar RM
J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
[TBL] [Abstract][Full Text] [Related]
15. The pituitary-thyroid axis in acromegaly.
Eskildsen PC; Kruse A; Kirkegaard C
Horm Metab Res; 1988 Dec; 20(12):755-7. PubMed ID: 3146541
[TBL] [Abstract][Full Text] [Related]
16. Adrenergic modulation of growth hormone secretion in acromegaly: alpha- and beta-adrenergic blockade produce qualitatively normal responses but no effect on L-dopa suppresion.
Cryer PE; Daughaday WH
J Clin Endocrinol Metab; 1977 May; 44(5):977-9. PubMed ID: 870520
[TBL] [Abstract][Full Text] [Related]
17. Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man.
Masturzo P; De Maria A; Murialdo G; Bonura ML; Zauli C; Polleri A
J Clin Endocrinol Metab; 1985 Aug; 61(2):378-81. PubMed ID: 4008612
[TBL] [Abstract][Full Text] [Related]
18. [The correlationship between basal prolactin levels and the suppressive effect of CB-154 or L-DOPA on GH release in acromegalic patients (author's transl)].
Hara I; Kataoka K; Tomita A; Takanohashi M; Nakane T; Kuwayama A; Kageyama N
Nihon Naibunpi Gakkai Zasshi; 1979 Jan; 55(1):16-24. PubMed ID: 581754
[TBL] [Abstract][Full Text] [Related]
19. Effect of pyridoxine on human hypophyseal trophic hormone release: a possible stimulation of hypothalamic dopaminergic pathway.
Delitala G; Masala A; Alagna S; Devilla L
J Clin Endocrinol Metab; 1976 Mar; 42(3):603-6. PubMed ID: 1254699
[TBL] [Abstract][Full Text] [Related]
20. Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients.
De Marinis L; Mancini A; Zuppi P; Fiumara C; Conte G; Sammartano L; Fabrizi ML; Valle D
Exp Clin Endocrinol Diabetes; 1996; 104(1):67-71. PubMed ID: 8750573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
